Drug
Etx 929 Dose Escalation
Etx 929 Dose Escalation: highest development phase Phase 1/2, developed by Ensem Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ensem Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ETX-929 dose escalation NCT07912593 | Phase 1/2 | Metastatic Colorectal Cancer (CRC) |
Latest
No recent events.
Follow Etx 929 Dose Escalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.